Paul Tapang

1.5k citations

29 papers · 773 indexed · h-index 14

Impact in

Hematology top 10%
- Multiple Myeloma Research and Treatments
Oncology top 10%
- Cancer-related Molecular Pathways
- Peptidase Inhibition and Analysis

Papers in

Hematology 4
- Chronic Myeloid Leukemia Treatments 3
- Acute Myeloid Leukemia Research 2
Genetics 3

Co-authors: Joel Johansson Daniel H. Albert Steven K. Davidsen Vincent L. Giranda Ran Guan Daniel Albert Yan Luo Michael L. Curtin
Journals: Bioorganic & Medicinal Chemistry Letters (6 papers)Journal of Pharmacology and Experimental Therapeutics (4 papers)Cancer Research (4 papers)Molecular Cancer Therapeutics (2 papers)Blood (2 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Paul Tapang

28 papers receiving 758 citations

Peers

Countries citing papers authored by Paul Tapang

Since Specialization

Citations

This map shows the geographic impact of Paul Tapang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Tapang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Tapang more than expected).

Fields of papers citing papers by Paul Tapang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Tapang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Tapang. The network helps show where Paul Tapang may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Paul Tapang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Paul Tapang Line = papers co-authored together Paul Tapang links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models Molecular Cancer Therapeutics ·Elizabeth A. Punnoose, Joel Johansson, Franklin Peale, Erwin R. Boghaert, Lisa D. Belmont, Nguyen Tan, A. Young, Michael J. Mitten, Ellen Ingalla, Walter C. Darbonne, Anatol Oleksijew, Paul Tapang, Yue Peng, Jason Oeh, Leslie Lee, Sophie Maïga, Wayne J. Fairbrother, Martine Amiot, Andrew J. Souers, Deepak Sampath	2016	223
2	CDK9 Inhibition Reverses Resistance to ABT-199 (GDC-0199) By Down-Regulating MCL-1 Blood ·Jun Chen, Sha Jin, Paul Tapang, Stephen K. Tahir, Morey L. Smith, John Xue, Haichao Zhang, Wenqing Gao, Yunsong Tong, Richard J. Clark, Justin L. Ricker, Thomas D. Penning, Daniel H. Albert, Darren C. Phillips, Andrew J. Souers, Joel Johansson	2014	1
3	Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families Bioorganic & Medicinal Chemistry Letters ·Michael L. Curtin, Robin R. Frey, H. Robin Heyman, Niru B. Soni, Patrick A. Marcotte, Lori J. Pease, Keith B. Glaser, Terrance J. Magoc, Paul Tapang, Daniel H. Albert, Donald J. Osterling, Amanda M. Olson, Jennifer J. Bouska, Zhiwen Guan, Lee C. Preusser, James S. Polakowski, Kent D. Stewart, Chris Tse, Steven K. Davidsen, Michael R. Michaelides	2012	19
4	FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model Cancer Chemotherapy and Pharmacology ·Sarah R. Mudd, Martin J. Voorbach, David R. Reuter, Paul Tapang, Jonathan A. Hickson, Lilibeth B. Edaño, Gerard B. Fox, Daniel H. Albert, Yanping Luo, Mark L. Day	2012	4
5	ABT-869, a Multitargeted Receptor Tyrosine Kinase Inhibitor, Reduces Tumor Microvascularity and Improves Vascular Wall Integrity in Preclinical Tumor Models Journal of Pharmacology and Experimental Therapeutics ·Fang Jiang, Daniel H. Albert, Yanping Luo, Paul Tapang, Ke Zhang, Steven K. Davidsen, Gerard B. Fox, Richard R. Lesniewski, Evelyn McKeegan	2011	17
6	Pharmacodynamic Evaluation of Irinotecan Therapy by FDG and FLT PET/CT Imaging in a Colorectal Cancer Xenograft Model Molecular Imaging and Biology ·Sarah R. Mudd, Sandy Ratna Puspitaningrum, Martin J. Voorbach, Todd Cole, David R. Reuter, Paul Tapang, Gail Bukofzer, Arunava Chakravartty, Cherrie K. Donawho, Joann P. Palma, Gerard B. Fox, Mark L. Day, Yanping Luo	2011	17
7	Identification of genes that confer tumor cell resistance to the Aurora B kinase inhibitor, AZD1152 The Pharmacogenomics Journal ·Jun Guo, Margeret Shandor Miles, Paul Tapang, Joann P. Palma, Luis E. Rodrı́guez, Ardi Septiawan, SATOSHI KIKUCHI, Jennifer J. Bouska, Abiodun Ogunmoroti, Dimitri Semizarov, Daniel H. Albert, Cherrie K. Donawho, Keith B. Glaser, O. Jameel Shah	2009	27
8	Effect of the Multitargeted Receptor Tyrosine Kinase Inhibitor, ABT-869 [N-(4-(3-Amino-1H-indazol-4-yl)phenyl)-N′-(2-fluoro-5-methylphenyl)urea], on Blood Pressure in Conscious Rats and Mice: Reversal with Antihypertensive Agents and Effect on Tumor Growth Inhibition Journal of Pharmacology and Experimental Therapeutics ·К В Душенко, Patricia N. Banfor, Paul Tapang, Jason A. Segreti, D. L. Widomski, Ece Inal, William T. Noonan, Gary A. Gintant, Steven K. Davidsen, Daniel H. Albert, Ryan M. Fryer, Bryan F. Cox	2009	16
9	Small Interfering RNA–Mediated Polo-Like Kinase 1 Depletion Preferentially Reduces the Survival of p53-Defective, Oncogenic Transformed Cells and Inhibits Tumor Growth in Animals Cancer Research ·Ran Guan, Paul Tapang, Joel Johansson, Daniel Albert, Vincent L. Giranda, Yan Luo	2005	122
10	ABT-869 a novel multi-targeted receptor tyrosine kinase inhibitor: characterization of FLT3 phosphorylation in a model of acute myelogenous leukemia Cancer Research ·Junling Li, Lori J. Pease, Paul Tapang, Jennifer McCall, Francisco Thiesen, Daniel H. Albert, Yujia Dai, Roger W. Bradley, Michael R. Michaelides, Steven K. Davidsen, Keith B. Glaser	2005	0
11	The Multi-Targeted Receptor Tyrosine Kinase Inhibitor, ABT-869, Induces Apoptosis of AML Cells Both In Vitro and In Vivo. Blood ·Deepa Shankar, Jenny Chia-Chen Chang, Yaoming Wang, Salemiz Sandoval, Junling Li, Francisco Thiesen, Paul Tapang, Steven K. Davidsen, S. Ruggerone, Keith B. Glaser, Theodore B. Moore, Kathleen M. Sakamoto	2005	2
12	Indole amide hydroxamic acids as potent inhibitors of histone deacetylases Bioorganic & Medicinal Chemistry Letters ·Yujia Dai, Yan Guo, Jun Guo, Lori J. Pease, Junling Li, Patrick A. Marcotte, Keith B. Glaser, Paul Tapang, Daniel H. Albert, Paul L. Richardson, Steven K. Davidsen, Michael R. Michaelides	2003	34
13	α-Keto amides as inhibitors of histone deacetylase Bioorganic & Medicinal Chemistry Letters ·Carol K. Wada, Robin R. Frey, Zhiqin Ji, Michael L. Curtin, Robert B. Garland, James H. Holms, Junling Li, Lori J. Pease, Jun Guo, Keith B. Glaser, Patrick A. Marcotte, Paul L. Richardson, Licheng Lu, Jennifer J. Bouska, Paul Tapang, Terrance J. Magoc, Daniel H. Albert, Steven K. Davidsen, Michael R. Michaelides	2003	67
14	ABT-491, a highly potent and selective PAF antagonist, inhibits nasal vascular permeability associated with experimental allergic rhinitis in Brown Norway rats Inflammation Research ·Daniel H. Albert, Paul Tapang, Douglas W. Morgan, Michael L. Curtin, George S. Sheppard, Steven K. Davidsen, James B. Summers, Geremia Balletta	1997	6
15	Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist European Journal of Pharmacology ·Daniel H. Albert, Terrance J. Magoc, Paul Tapang, Norbert Wermes, Douglas W. Morgan, Michael L. Curtin, George S. Sheppard, Lianhong Xu, H. Robin Heyman, Steven K. Davidsen, James B. Summers, George W. Carter	1997	25
16	Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist. Journal of Pharmacology and Experimental Therapeutics ·Daniel H. Albert, Richard G. Conway, Terrance J. Magoc, Paul Tapang, B. Kuchenmüller, Guanglin Luo, James H. Holms, Steven K. Davidsen, James B. Summers, Inês Sousa e Silva Boavida Portugal	1996	5
17	ABT-299, A NOVEL PAF ANTAGONIST, ATTENUATES MULTIPLE EFFECTS OF ENDOTOXEMIA IN CONSCIOUS RATS Shock ·Daniel H. Albert, Norbert Wermes, Terrance J. Magoc, Paul Tapang, James H. Holms, Steven K. Davidsen, James B. Summers, George W. Carter	1996	12
18	ABT-299, a potent antagonist of platelet activating factor. PubMed ·Zelmira Walkiria Blas Hernández, George Jefferson Greene, Indri Herdiana, Richard G. Conway, Emma Graciela, Sophie Kligler, Guanglin Luo, Paul Tapang, B. Kuchenmüller, Inês Sousa e Silva Boavida Portugal	1995	2
19	Synthesis of active metabolites of indole pyrrolothiazole paf antagonists Bioorganic & Medicinal Chemistry Letters ·Steven K. Davidsen, James B. Summers, David J. Sweeny, James H. Holms, Daniel H. Albert, George M. Carrera, Paul Tapang, Terrance J. Magoc, Richard G. Conway, B. Kuchenmüller	1995	6
20	Synthesis and evaluation of water soluble indole pyrrolothiazole paf antagonists Bioorganic & Medicinal Chemistry Letters ·George S. Sheppard, Steven K. Davidsen, George M. Carrera, Daisy Pireh, James H. Holms, H. Robin Heyman, Douglas H. Steinman, Michael L. Curtin, Richard G. Conway, B. Kuchenmüller, Daniel H. Albert, Paul Tapang, Terrance J. Magoc, James B. Summers	1995	3

About Paul Tapang

Paul Tapang is a scholar working on Hematology, Genetics, Oncology, Cell Biology and Pharmacology, having authored 29 papers that have together received 773 indexed citations. Recurring topics across this work include Microtubule and mitosis dynamics (4 papers), Protein Degradation and Inhibitors (4 papers), Chronic Myeloid Leukemia Treatments (3 papers), Cancer therapeutics and mechanisms (3 papers), Cancer-related Molecular Pathways (3 papers), Lung Cancer Treatments and Mutations (3 papers), Acute Myeloid Leukemia Research (2 papers) and Medical Imaging Techniques and Applications (2 papers). The work is most often cited by research in Hematology (149 citations), Oncology (236 citations), Cell Biology (123 citations), Genetics (79 citations) and Molecular Biology (444 citations). Paul Tapang has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Joel Johansson, Daniel H. Albert, Steven K. Davidsen, Vincent L. Giranda, Ran Guan, Daniel Albert, Yan Luo, Michael L. Curtin, Patrick A. Marcotte and Andrew J. Souers. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, Journal of Pharmacology and Experimental Therapeutics, Cancer Research, Molecular Cancer Therapeutics and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact